SLE still an enigma where both patient and health care professionals are blind and do more harm than saving the patient. Hope in future anything can be done to save the patient from the grip of lupus,
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value.
SLE still an enigma where both patient and health care professionals are blind and do more harm than saving the patient. Hope in future anything can be done to save the patient from the grip of lupus,
Module: Pharmacotherapy III
Module Coordinator: Dr. Arwa M. Amin Mostafa
Academic Level: Postgraduate, Master of Pharmacy in Clinical Pharmacy
School: Dubai Pharmacy College
Year of first presented in Class: 2018
This presentation is for Educational purpose. It has no commercial value.
Recent Advances In The Management Of Juvenile Idiopathic ArthritisNaveen Kumar Cheri
The term “rheumatologicaldisorders” refers to diseases that affect the major connective tissues of the body (e.g. skin, bone, blood vessels, cartilage and basement membrane).
Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatologic disease. It is associated with significant long term morbidity.
It was previously called as, Juvenile Rheumatoid Arthritis (by ACR –American College of Rheumatology) or Juvenile Chronic Arthritis (by ELAR –European League Against Rheumatism).
Still's disease, sometimes referred to as Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain and a distinctive salmon-colored bumpy rash.
Collagen is most abundant protein in mammals, the main fibrous component of skin, bone, tendon and cartilage.
Collagen comprises one- third of the total protein, accounts for three-quarters of the dry weight of skin, and is the most prevalent component of the extracellular matrix.
The collagen family consists of 28 members and these are classified by Roman numbers on the basis of their chronology of discovery.
Kenneth C. Kalunian, MD, Maureen A. McMahon, MD, and Joan T. Merrill, MD, prepared useful practice aids pertaining to systemic lupus erythematosus for this CME activity titled "Candid Conversations in Lupus: Navigating Advances in Diagnosis and Treatment to Provide Optimal Care for Each Patient." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at https://bit.ly/2zki5EQ. CME credit will be available until September 14, 2021.
45. Randomized study of maintenance Rx Cyclo, azathioprine and MMF Contreras, G. et al. N Engl J Med 2004;350:971-980
46. Randomized study of maintenance Rx Cyclo, azathioprine and MMF Contreras, G. et al. N Engl J Med 2004;350:971-980 Kaplan-Meier Estimates of Relapse-free Survival
47. Induction therapy: Mycophenolate Mofetil Vs Cyclophosphamide Chan, T. M. et al. N Engl J Med 2000;343:1156-1162 Outcome of Treatment Chan, T. M. et al. N Engl J Med 2000;343:1156-1162
48. Chan, T. M. et al. N Engl J Med 2000;343:1156-1162 Mean ({+/-}SD) Serum Albumin Concentration and Urinary Protein Excretion in Patients with Diffuse Proliferative Lupus Nephritis Who Were Treated with Mycophenolate Mofetil and Prednisolone (Group 1) or with Cyclophosphamide and Prednisolone Followed by Azathioprine and Prednisolone (Group 2)
Figure 3. Kaplan-Meier Estimates of Relapse-free Survival.
Table 3. Outcome of Treatment.
Figure 2. Mean ({+/-}SD) Serum Albumin Concentration and Urinary Protein Excretion in Patients with Diffuse Proliferative Lupus Nephritis Who Were Treated with Mycophenolate Mofetil and Prednisolone (Group 1) or with Cyclophosphamide and Prednisolone Followed by Azathioprine and Prednisolone (Group 2). The mean serum albumin concentration was significantly higher than the base-line value after two weeks of therapy in group 2 and after four weeks of therapy in group 1, and it remained significantly higher at each subsequent evaluation (P<0.05 for the comparisons in each group). Urinary protein excretion was significantly lower than the base-line value after two weeks of therapy in group 1 and after four weeks of therapy in group 2, and it remained significantly lower at each subsequent evaluation (P<0.05 for the comparisons in each group). The numbers below the panels are numbers of patients for whom data were available.
![SLE ,[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)